Analysis of the expression of lymphoid enhancer binding factor 1 in B cell chronic lymphoproliferative disor-ders
10.3969/j.issn.1006-5725.2024.07.018
- VernacularTitle:淋巴样增强结合因子1在B细胞慢性淋巴增殖性疾病中的表达
- Author:
Min ZHAO
1
;
Ping NI
;
Huiying ZHAI
;
Xiaoke JIN
;
Yuqiong YANG
Author Information
1. 芜湖市第二人民医院血液内科(安徽芜湖 241000)
- Keywords:
B cell chroniclymphoproliferative disorders;
lymphoid enhancer binding factor 1;
chronic lymphocytic leukemia;
diagnosis
- From:
The Journal of Practical Medicine
2024;40(7):984-988
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the expression of lymphoid enhancer binding factor 1(LEF1)in B cell chronic lymphoproliferative disorders(B-CLPD)and estimate its value in the differential diagnosis of the subtype of B-CLPD.Methods A retrospective study was conducted on 58 patients diagnosed with B-CLPD by using bone marrow biopsy samples or lymphnode biopsy samples from Hematology Department of The Second People′s Hospital of Wuhu from September 2018 to June 2023,as well as 20 bone marrow biopsy samples which were diagnosis as non-hematologic malignancy in the control group.Immunohistochemical method was used to detect the expression of LEF1 in 78 samples,and statistical analysis was conducted.Results In all 78 cases,16 of 20 chronic lymphocytic leukemia(CLL)patients were LEF1 positive,the positive rate was 80%;mantle cell lymphoma 1/12;Follicular lymphoma 1/5;marginal zone cell lymphoma 0/11;Lymphoplasmacyticlymphom 0/8;hairy cell leukemia 0/2;in Control group no patient was LEF1 positive(P = 0.000).The expression of LEF1 is correlated with CD200 and CLL score(P<0.05).In the LEF1 negative group with 4 CLL patients,2 were detected with +12 chromosomal abnormality,the detective rate was higher than that of the LEF1 positive group(P>0.05).Conclusion LEF1 was a sensitive and specific diagnosis marker in CLL and B-CLPD subtype.
